Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy?

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] Company Overview: Xeris Biopharma (XERS) - Xeris Biopharma currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Performance Metrics - XERS shares have increased by 5.96% over the past week, outperforming the Zacks Medical - Drugs industry, which remained flat [5] - Over the past quarter, XERS shares have risen by 57.69%, and by 178.86% over the last year, significantly outperforming the S&P 500's gains of 8.19% and 19.01% respectively [6] Trading Volume - The average 20-day trading volume for XERS is 2,056,227 shares, indicating a bullish trend when combined with rising stock prices [7] Earnings Outlook - In the past two months, three earnings estimates for XERS have been revised upwards, with the consensus estimate improving from -$0.07 to -$0.03 [9] - For the next fiscal year, three estimates have also moved higher, with no downward revisions noted [9] Conclusion - Given the strong performance metrics and positive earnings outlook, Xeris Biopharma is positioned as a promising investment opportunity with a Momentum Score of A [11]